In a new paper published this week in Cancer Cell, Mayo Clinic researchers provide genetic evidence that Ect2 drives lung adenocarcinoma tumour formation.

"This paper demonstrates, for the first time, that Ect2 is required for tumour formation in vivo and identifies a novel function related to ribosomes for Ect2 in lung adenocarcinoma tumour cells," says Alan Fields, Ph.D., senior author on the paper.

Dr. Fields is a cancer biologist and the Monica Flynn Jacoby Professor of Cancer Research in the Department of Cancer Biology at Mayo Clinic's Florida campus.

Lung adenocarcinoma accounts for 40 percent of lung cancer diagnoses according to Dr. Fields.

And the most frequent driver of this cancer is a mutation in the KRAS gene.

"KRAS-mediated lung adenocarcinoma is a particularly deadly form of lung cancer, in part because attempts to directly target KRAS therapeutically have not been successful in the clinic," says the study's lead author, Verline Justilien, Ph.D., an assistant professor in the Department of Cancer Biology at Mayo Clinic's Florida campus.

In normal cells Ect2 directs the last step of cell division, called cytokinesis.

"Surprisingly however, we found that Ect2 is not necessary for cytokinesis in lung adenocarcinoma cells, indicating that there must be some other function for Ect2 that tumour cells require," says Dr. Fields.

In this paper the team reports that the other function is to boost ribosome production. Ribosomes are cellular machines which manufacture proteins from messenger RNA instructions.

"As a consequence, Ect2 drives increased synthesis of ribosomal RNA, which in turn gives rise to increased ribosomes," says Dr. Fields. "While it's been known for a long time that tumour cells have elevated ribosome levels, this paper is the first to show that Ect2 supports tumour cell growth by stimulating ribosome biogenesis."

In their previous work, Drs. Fields and Justilien implicated another lung cancer gene in controlling the activity of Ect2 in this disease model.

This second gene, protein kinase Cι (PKCι), was first identified in Dr. Fields' laboratory. Previously the team published a study in Cancer Cell on auranofin, a PKCι-inhibitor.

When used with a second experimental agent, the combination shuts down lung adenocarcinoma tumour growth.

The current Cancer Cell paper indicates that inhibition of Ect2, and subsequently ribosome synthesis, is a major mechanism by which auranofin works.

"Our current findings reveal a potential novel therapeutic strategy for treating mutant KRAS lung adenocarcinoma cells in which Ect2 is overexpressed," Dr. Justilien says.

Based on preclinical research from Dr. Fields' team, Mayo Clinic is conducting early-phase clinical trials of auranofin.

These studies will test the effectiveness of the compound alone and in targeted combinations.

Trials will focus on patients with KRAS-mediated lung adenocarcinoma, lung squamous cell carcinoma, and ovarian cancer.

Source: Mayo Clinic